3 Top Biotech ETFs That Weathered the VRX Drop
The iShares Biotechnology ETF (NYSE Arca: IBB) has a market cap of $8.2 billion and 143 positions. The ETF’s holdings include pharma giants like Gilead Sciences Inc. (Nasdaq: GILD), Amgen Inc. (Nasdaq: AMGN), Celgene Corp. (Nasdaq: CELG), Regeneron Pharmaceuticals Inc. (Nasdaq: REGN), and Biogen Inc. (Nasdaq: BIIB). You won’t, however, find Valeant here. IBB ended last week with 0.6% gain. Year to date, IBB is up 6%.
The ProShares Ultra Nasdaq Biotechnology ETF (NYSE Arca: BIB) seeks daily investment results that correspond to two times the daily performance of the Nasdaq Biotechnology Index. As a Nasdaq Biotech Index tracking ETF, it also doesn’t hold Valeant. Shares ended last week with 0.7% gain. BIB is up 3.2% over the last month and 4.8% year to date.
The Health Care Select SPDR ETF (NYSE Arca: XLV) boasts a market cap of $13.33 billion. Its diversified portfolio includes drug goliaths Pfizer Inc. (NYSE:PFE), Johnson & Johnson (NYSE: JNJ), and Merck & Co. Inc. (NYSE: MRK). Large and small biotech firms are also among holdings. Shares ended last week nearly flat but are up 4.1% over the last month. XLV has gained 3.1% in 2015.
We’re in the midst of the greatest investing boom in almost 60 years. And rest assured – this boom is not about to end anytime soon. You see, the flattening of the world continues to spawn new markets worth trillions of dollars; new customers that measure in the billions; an insatiable global demand for basic resources that’s growing exponentially; and a technological revolution even in the most distant markets on the planet.And Money Morning is here to help investors profit handsomely on this seismic shift in the global economy. In fact, we believe this is where the only real fortunes will be made in the months and years to come.